Morgan Stanley ($MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...

YaoPharma will complete the ongoing Phase 1 study before handing development rights to Pfizer. ・YaoPharma will receive a $150 ...

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent ...

As of the close of business on December 5, around 60% of the 26 Wall Street analysts with recommendations on Pfizer have a ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...

Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc.

Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a ...

Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $543,015, and 18 were calls, valued ...